ALNYLAM
Alnylam Pharmaceuticals, Inc.
Application Filed: 2018-05-18
Trademark Application Details
PUBLICATION/ISSUE REVIEW COMPLETE
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87927601 |
| Registration Number | 6739619 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Ann Lamport Hammitte |
| Attorney Docket Number | A2038-2034 |
| Law Office Assigned | M10 |
| Employee Name | VOHRA, SANJEEV KUMAR |
Timeline
| 2018-05-18 | Application Filed |
| 2019-01-07 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-01-07 | Status: Live/Pending |
| 2019-01-08 | Transaction Date |
| 2019-02-12 | Published for Opposition |
| 2022-05-24 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Alnylam Pharmaceuticals, Inc. |
| Address | 300 Third Street, 3rd Floor Cambridge DE 02142 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of ocular diseases; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of ocular diseases |
| GS0051 | Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), hereditary ATTR amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1, Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), porphyria, hereditary ATTR amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1 |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2018-05-22 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-05-26 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2018-06-11 | 3 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-06-19 | 4 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2018-06-19 | 5 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-06-19 | 6 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2018-12-12 | 7 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-12-12 | 8 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-12-12 | 9 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-12-12 | 10 CNSA P: |
| ASSIGNED TO LIE | 2019-01-07 | 11 ALIE A:Allowance for Publication |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-01-23 | 12 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2019-02-12 | 13 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-02-12 | 14 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-04-09 | 15 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-10-09 | 16 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2019-10-09 | 17 EXT1 S: |
| EXTENSION 1 GRANTED | 2019-10-09 | 18 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-10-11 | 19 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-03-30 | 20 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2020-03-30 | 21 EXT2 S: |
| EXTENSION 2 GRANTED | 2020-03-30 | 22 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-04-01 | 23 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-10-07 | 24 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2020-10-07 | 25 EXT3 S: |
| EXTENSION 3 GRANTED | 2020-10-07 | 26 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-10-09 | 27 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2021-04-09 | 28 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2021-04-09 | 29 EXT4 S: |
| EXTENSION 4 GRANTED | 2021-04-09 | 30 EX4G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-04-13 | 31 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2021-09-09 | 32 EEXT I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2021-09-15 | 33 AITU A:Allowance for Publication |
| EXTENSION 5 FILED | 2021-09-09 | 34 EXT5 S: |
| EXTENSION 5 GRANTED | 2021-09-15 | 35 EX5G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-09-16 | 36 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2022-04-08 | 37 EISU I:Incoming Correspondence |
| USE AMENDMENT FILED | 2022-04-08 | 38 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2022-04-19 | 39 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2022-04-20 | 40 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2022-04-21 | 41 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2022-05-24 | 42 R.PR A:Allowance for Publication |
| NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2022-05-25 | 43 NRCC E:E-Mail |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2023-03-30 | 44 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2023-03-30 | 45 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2023-03-30 | 46 TCCA I:Incoming Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ALNYLAM 87927601 not registered Live/Pending |
Alnylam Pharmaceuticals, Inc. 2018-05-18 |
 ALNYLAM 78145702 2779537 Live/Registered |
Alnylam Pharmaceuticals Inc. 2002-07-19 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 